Delivery Order SPE2DR25D1205-SPE2DR26F0WL4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $29,328.80 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed price, competitively awarded delivery order represents non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $18,061.85 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 5, 2025, with completion expected by November 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $13,841.99 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $44,922.09 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packages) valued at $3,111.66. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The ultimate completion date is October 30, 2025, and the product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0WL4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) valued at $49,686.94 under a firm fixed-price contract. The award, issued on November 7, 2025, with completion targeted for November 10, 2025, represents a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same city. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs. RINVOQ ER, a JAK inhibitor used in the treatment of rheumatoid arthritis, represents one of the specialized pharmaceutical products available through this contract vehicle that serves the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.7k | 11/7/25 |